FilingReader Intelligence
Laurus Labs reports 31% revenue growth in Q1
July 25, 2025 at 09:59 AM UTC•By FilingReader AI
Laurus Labs reported revenues of ₹1,570 crore for Q1-FY26, up 31% year-on-year, driven by robust CDMO performance and generic formulations, partially offset by lower API business.
EBITDA surged 127% to ₹389 crore, delivering a margin of 24.8%. Net profit jumped 1,154% to ₹163 crore.
The company's CDMO small molecules segment achieved 130% year-on-year growth. Laurus invested ₹265 crore in capex during the quarter, representing 17% of sales.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
BSE:LAURUSLABS•Bombay Stock Exchange
News Alerts
Get instant email alerts when Laurus Labs publishes news
Free account required • Unsubscribe anytime